Testing rituximab plus AB-101 for autoimmune diseases
Treatments studied
Part of Bones, joints & muscles, Heart & circulation, Immune system & allergy, Lungs & breathing, Skin clinical trials.
This trial tests a new treatment (AB-101) combined with rituximab for people with certain autoimmune diseases like rheumatoid arthritis, pemphigus vulgaris, vasculitis, or lupus. It is for those who have not had success with standard therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have one of these conditions: rheumatoid arthritis, pemphigus vulgaris, vasculitis (GPA/MPA), or lupus.
- You have tried at least two standard treatments for your condition and they didn't work or caused side effects.
- You are taking a stable, low dose of steroids (less than 20 mg prednisone a day) for at least a month.
- You have not had rituximab or other similar treatments in the last 3 months, and no prior cell therapy.
- Your heart, lungs, kidneys, and blood counts meet specific healthy levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new drug called ABBV-519 given as infusions or injections to treat systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) in adults whose disease hasn't responded well to other treatments. Researchers will measure how safe the drug is, how it moves through your body, and whether it helps reduce symptoms.
This trial tests if a new medication, AZD0120, is safe for people with autoimmune diseases. It aims to help patients by targeting the immune system.
This trial tests a new cell therapy called UTAA91 for people with autoimmune diseases that have not responded to standard treatments. It aims to see if this treatment can help control the disease.
This trial tests two study drugs, inebilizumab and blinatumomab, for people with lupus (SLE) or rheumatoid arthritis (RA) that hasn't gotten better with standard treatments. It focuses on those with active disease, especially lupus-related kidney problems.
This study tests a new drug called HBM7020 to see how safe it is and how your body processes it. The trial includes healthy volunteers and people with autoimmune diseases like lupus, rheumatoid arthritis, or scleroderma to understand if the drug might help reduce disease activity.
This trial tests a new drug called GSK5926371 for people with certain autoimmune diseases that affect the joints, skin, and other tissues. It aims to see if the drug is safe and how well it works.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.